David A. Nathanson

University of California, Los Angeles — United States

Medicine · Health Sciences

34h-index6.4kcitations385works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(97), RNA modifications and cancer(67), Immunotherapy and Immune Responses(63), Histone Deacetylase Inhibitors Research(37), Cancer Research and Treatments(37)

Publications385 total

A human tumor-immune organoid model of glioblastoma
Cell Reports·2026· 2 citedOpen Access
Beyond Cell Cycle Control: <i>CDKN2A</i> Loss Orchestrates NAD <sup>+</sup> Metabolic Plasticity and NAMPT Inhibitor Sensitivity in Glioblastoma
2025Open Access
Supplementary Data 1 from Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma
2025Open Access
Supplemental Figure S1 from Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma
2025Open Access
Supplemental Figure S2 from Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma
2025Open Access
STEM-23. GBM NEURODEVELOPMENTAL LINEAGE PLASTICITY DRIVES RAPID ADAPTATION TO ONCOGENE TARGETED THERAPY
Neuro-Oncology·2025Open Access
IMMU-36. iHOTT: A Human Tumor–Immune Organoid Model for Interrogating Immunotherapy Response in Glioblastoma
Neuro-Oncology·2025Open Access
TMET-40. Proneural Glioblastomas Exhibit Altered Lipid Metabolism That Promotes Susceptibility to Non-Canonical Cell Death
Neuro-Oncology·2025Open Access
DDDR-67. BMP signaling modulates apoptotic and non-apoptotic cell death in glioblastoma
Neuro-Oncology·2025Open Access
EXTH-02. GliomaPDOX – A direct brain-to-brain glioma xenograft library for drug discovery and development
Neuro-Oncology·2025Open Access
EXTH-08. BRD2 bromodomain-mediated regulation of cell state plasticity modulates therapy response in glioblastoma
Neuro-Oncology·2025Open Access
Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safety
Molecular Therapy·2025· 4 citedOpen Access
Identifying and exploiting combinatorial synthetic lethality by characterizing adaptive kinome rewiring of EGFRvIII-driven glioblastoma
UNC Libraries·2025Open Access
BRD2 bromodomain-mediated regulation of cell state plasticity modulates therapy response in glioblastoma
Neuro-Oncology·2025Open Access
Identifying and exploiting combinatorial synthetic lethality by characterizing adaptive kinome rewiring of EGFRvIII-driven glioblastoma
Acta Neuropathologica Communications·2025Open Access
A Human Tumor-Immune Organoid Model of Glioblastoma
2025· 1 citedOpen Access
Impact of corticosteroid administration on contrast-enhancing volume and diffusion MRI in treatment naïve glioblastoma
Neuro-Oncology·2025· 3 citedOpen Access
Tegavivint triggers TECR-dependent nonapoptotic cancer cell death
Nature Chemical Biology·2025· 4 cited
EGFR, the Lazarus target for precision oncology in glioblastoma
UNC Libraries·2025Open Access
Corrigendum to: EGFR, the Lazarus target for precision oncology in glioblastoma
UNC Libraries·2025Open Access
page 1 of 20Next →

Frequent Co-authors

Timothy F. Cloughesy(22), Paul S. Mischel(13), William H. Yong(10), Linda M. Liau(10), Harley I. Kornblum(9), Webster K. Cavenee(8), Robert M. Prins(8), Caius G. Radu(7), Jonathan Tsang(6), Shaojun Zhu(6), Richard G. Everson(6), Steven J. Bensinger(6), Lisa Ta(6), Frank B. Furnari(5), Beatrice Gini(5), James R. Heath(5), David Akhavan(5), Ivan Babić(5), Kazuhiro Tanaka(5), Julie Dang(5)